Experts InSight Update on Intravitreal Injectable Drugs and Dry AMD Treatments
Aug 10, 2023
Drs. M. Ali Khan, Ajay Kuriyan, and Sarah Read discuss recent developments in intravitreal injectable drugs, including 8-mg aflibercept not approved by FDA, PDUFA date for on-label bevacizumab, and injections for dry AMD. They explore step therapy, biosimilars, and the impact on costs and access. They also cover treatment options and decision-making for AMD patients with geographic atrophy. A casual basketball conversation concludes the podcast.
Chapters
Transcript
Episode notes
1 2 3 4 5 6
Introduction
00:00 • 3min
FDA Rejection and Uncertainty in Stock Prices
02:43 • 8min
Exploring Step Therapy and Biosimilars
11:05 • 3min
The Impact of Biosimilars and FDA Approved Versions of Drugs on Costs and Access
13:35 • 6min
Treatment Options and Decision-Making for Geographic Atrophy in AMD Patients
19:52 • 18min
Casual Basketball Conversation and Closing Remarks
37:53 • 3min